Intuitive Surgical’s Q2 2026 da Vinci procedure growth market reflects balanced trader views around the company’s full-year 13.5-15.5% guidance, supported by the ongoing da Vinci 5 rollout that delivers roughly 11% higher utilization than the legacy Xi system. Q1 2026 results showed 16% da Vinci procedure growth and 23% revenue expansion to $2.77 billion, driven by system placements and recurring instruments revenue, prompting management to lift the annual outlook. Key swing factors include sustained utilization trends above 4% as the installed base shifts toward da Vinci 5, international adoption rates, and competitive positioning against emerging robotic platforms. With earnings set for July 16, near-term data on procedure volumes and margins will clarify whether growth remains in the mid-teens range or accelerates further amid strong demand for advanced surgical systems.
Polymarket 데이터를 참조하는 실험적 AI 생성 요약입니다. 이것은 거래 조언이 아니며 이 마켓의 정산에 영향을 미치지 않습니다. · 업데이트<12.5% 50%
12.5%-15% 50%
15%-17.5% 50%
17.5%-20% 50%
신규
신규
2026.07.16
<12.5%
50%
12.5%-15%
50%
15%-17.5%
50%
17.5%-20%
50%
20%+
49%
<12.5% 50%
12.5%-15% 50%
15%-17.5% 50%
17.5%-20% 50%
신규
신규
2026.07.16
<12.5%
$233 거래량
50%
12.5%-15%
$0 거래량
50%
15%-17.5%
$0 거래량
50%
17.5%-20%
$0 거래량
50%
20%+
$0 거래량
49%
This market will resolve according to Intuitive Surgical's da Vinci procedure growth for the upcoming second fiscal quarter, as reported in its official company earnings materials.
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to the lowest bracket.
If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to the lowest bracket.
If the reported value falls exactly between two brackets, this market will resolve to the higher range bracket.
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.Intuitive Surgical’s Q2 2026 da Vinci procedure growth market reflects balanced trader views around the company’s full-year 13.5-15.5% guidance, supported by the ongoing da Vinci 5 rollout that delivers roughly 11% higher utilization than the legacy Xi system. Q1 2026 results showed 16% da Vinci procedure growth and 23% revenue expansion to $2.77 billion, driven by system placements and recurring instruments revenue, prompting management to lift the annual outlook. Key swing factors include sustained utilization trends above 4% as the installed base shifts toward da Vinci 5, international adoption rates, and competitive positioning against emerging robotic platforms. With earnings set for July 16, near-term data on procedure volumes and margins will clarify whether growth remains in the mid-teens range or accelerates further amid strong demand for advanced surgical systems.
This market will resolve according to Intuitive Surgical's da Vinci procedure growth for the upcoming second fiscal quarter, as reported in its official company earnings materials.
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to the lowest bracket.
If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to the lowest bracket.
If the reported value falls exactly between two brackets, this market will resolve to the higher range bracket.
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to the lowest bracket.
If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to the lowest bracket.
If the reported value falls exactly between two brackets, this market will resolve to the higher range bracket.
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
마켓 개설일: Jul 8, 2026, 7:06 PM ET
거래량
$233종료일
2026.07.16마켓 개설일
Jul 8, 2026, 7:06 PM ETResolver
0x69c47De9D...This market will resolve according to Intuitive Surgical's da Vinci procedure growth for the upcoming second fiscal quarter, as reported in its official company earnings materials.
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to the lowest bracket.
If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to the lowest bracket.
If the reported value falls exactly between two brackets, this market will resolve to the higher range bracket.
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.Intuitive Surgical’s Q2 2026 da Vinci procedure growth market reflects balanced trader views around the company’s full-year 13.5-15.5% guidance, supported by the ongoing da Vinci 5 rollout that delivers roughly 11% higher utilization than the legacy Xi system. Q1 2026 results showed 16% da Vinci procedure growth and 23% revenue expansion to $2.77 billion, driven by system placements and recurring instruments revenue, prompting management to lift the annual outlook. Key swing factors include sustained utilization trends above 4% as the installed base shifts toward da Vinci 5, international adoption rates, and competitive positioning against emerging robotic platforms. With earnings set for July 16, near-term data on procedure volumes and margins will clarify whether growth remains in the mid-teens range or accelerates further amid strong demand for advanced surgical systems.
This market will resolve according to Intuitive Surgical's da Vinci procedure growth for the upcoming second fiscal quarter, as reported in its official company earnings materials.
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to the lowest bracket.
If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to the lowest bracket.
If the reported value falls exactly between two brackets, this market will resolve to the higher range bracket.
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to the lowest bracket.
If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to the lowest bracket.
If the reported value falls exactly between two brackets, this market will resolve to the higher range bracket.
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
거래량
$233종료일
2026.07.16마켓 개설일
Jul 8, 2026, 7:06 PM ETResolver
0x69c47De9D...Intuitive Surgical’s Q2 2026 da Vinci procedure growth market reflects balanced trader views around the company’s full-year 13.5-15.5% guidance, supported by the ongoing da Vinci 5 rollout that delivers roughly 11% higher utilization than the legacy Xi system. Q1 2026 results showed 16% da Vinci procedure growth and 23% revenue expansion to $2.77 billion, driven by system placements and recurring instruments revenue, prompting management to lift the annual outlook. Key swing factors include sustained utilization trends above 4% as the installed base shifts toward da Vinci 5, international adoption rates, and competitive positioning against emerging robotic platforms. With earnings set for July 16, near-term data on procedure volumes and margins will clarify whether growth remains in the mid-teens range or accelerates further amid strong demand for advanced surgical systems.
Polymarket 데이터를 참조하는 실험적 AI 생성 요약입니다. 이것은 거래 조언이 아니며 이 마켓의 정산에 영향을 미치지 않습니다. · 업데이트
외부 링크에 주의하세요.
외부 링크에 주의하세요.
자주 묻는 질문